Aminobenzisoxazole compounds as agonists of α7 nicotinic acetylcholine receptors: a patent evaluation (WO 2017027600)

References

• Forray C, Buller R. Challenges and opportunities for the development of new antipsychotic drugs. Biochem Pharmacol. 2017;143:10−24.
   PubMed Web of Science ®Google Scholar
• Bortolato B, Miskowiak KW, Köhler CA, et al. Cognitive remission: a novel objective for the treatment of major depression? BMC Med. 2016;14(1):9.
   PubMedGoogle Scholar
• Dineley KT, Pandya AA, Yakel JL. Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci. 2015;36(2):96−108.
   PubMed Web of Science ®Google Scholar
• Lendvai B, Kassai F, Szájli Á, et al. α7 nicotinic acetylcholine receptors and their role in cognition. Brain Res Bull. 2013;93:86−96.
   PubMed Web of Science ®Google Scholar
• De Jaco A, Bernardini L, Rosati J, et al. Alpha-7 nicotinic receptors in nervous system disorders: from function to therapeutic perspectives. Cent Nerv Syst Agents Med Chem. 2017;17(2):100−108.
   PubMedGoogle Scholar
• Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci. 2004;25(6):317−324.
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Hashimoto K. α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia. Curr Pharm Des. 2011;17(2):121−129.
   PubMed Web of Science ®Google Scholar
• Russo P, Del Bufalo A, Frustaci A, et al. Beyond acetylcholinesterase inhibitors for treating Alzheimer’s disease: α7-nAChR agonists in human clinical trials. Curr Pharm Des. 2014;20(38):6014−6021.
   PubMed Web of Science ®Google Scholar
• Barbier AJ, Hilhorst M, Van Vliet A, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies. Clin Ther. 2015;37(2):311−324.
   PubMed Web of Science ®Google Scholar
• Keefe RSE, Meltzer HA, Dgetluck N, et al. Randomized, double-blind, placebo-controlled study of encenicline, an α7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharm. 2015;40(13):3053−3060.
   PubMed Web of Science ®Google Scholar
• Kitagawa H, Takenouchi T, Azuma R, et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharm. 2003;28:542−551.
   PubMed Web of Science ®Google Scholar
• Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006;63(6):630−638.
   PubMed Web of Science ®Google Scholar
• Beinat C, Banister SD, Herrera M, et al. The recent development of α7 nicotinic acetylcholine receptor (nAChR) ligands as therapeutic candidates for the treatment of Central Nervous System (CNS) diseases. Curr Pharm Des. 2016;22(14):2134−2151.
   PubMed Web of Science ®Google Scholar
• Feuerbach D, Pezous N, Weiss M, et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol. 2015;172(5):1292−1304.
   PubMed Web of Science ®Google Scholar
• Wallace TL, Callahan PM, Tehim A, et al. RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther. 2011;336(1):242−253.
   PubMed Web of Science ®Google Scholar
• Tang M, Wang Z, Zhou Y, et al. A novel drug candidate for Alzheimer’s disease treatment: gx-50 derived from Zanthoxylum bungeanum. J Alzheimer’s Dis. 2013;34(1):203−213.
   PubMed Web of Science ®Google Scholar
• Corradi J, Bouzat C. Understanding the bases of function and modulation of α7 nicotinic receptors: implications for drug discovery. Mol Pharmacol. 2016;90(3):288−299.
   PubMed Web of Science ®Google Scholar
• Williams DK, Wang J, Papke RL. Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem Pharmacol. 2011;82(8):915−930.
   PubMed Web of Science ®Google Scholar
• Uteshev VV. The therapeutic promise of positive allosteric modulation of nicotinic receptors. Eur J Pharmacol. 2014;727:181−185.
   PubMed Web of Science ®Google Scholar
• Nikiforuk A, Kos T, Potasiewicz A, et al. Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats. Eur Neuropsychopharmacol. 2015;25(8):1300−1313.
   PubMed Web of Science ®Google Scholar
• Yang T, Xiao T, Sun Q, et al. The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials. Acta Pharm Sin B. 2017;7(6):611−622.
   PubMed Web of Science ®Google Scholar
• Acharya Raksha, Burnett Duane A, Bursavich Matthew Gregory, et al. Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors. WO 2017027600 A1. 2017.
   Google Scholar
• Burnett Duane A, Bursavich Matthew Gregory, McRiner Andrew J. Spiro-oxadiazoline compounds as agonists of α7-nicotinic acetylcholine receptors and their preparation. WO 2015066371 A1. 2015.
   Google Scholar
• Acharya Raksha, Burnett Duane A, Bursavich Matthew Gregory, et al. Preparation of aminoisoxazoline compounds as agonists of α7-nicotinic acetylcholine receptors. WO 2017069980 A1. 2017.
   Google Scholar
• Acharya Raksha, Burnett Duane A, Bursavich Matthew Gregory, et al. Preparation of geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors. WO 2016100184 A1. 2016.
   Google Scholar
• Acharya Raksha, Burnett Duane A, Bursavich Matthew Gregory, et al. Preparation of aminobenzisoxazole compounds as agonists of alpha-7 nicotinic acetylcholine receptors. WO 2016201096 A1. 2016.
   Google Scholar
• Norinder U, Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliv Rev. 2002;54:291–313.
   PubMed Web of Science ®Google Scholar
• Ghose AK, Herbertz T, Hudkins RL, et al. Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. ACS Chem Neurosci. 2011;3(1):50−68.
   PubMed Web of Science ®Google Scholar
• Chen SG, Gu RX, Dai H, et al. Virtual screening for alpha7 nicotinic acetylcholine receptor for treatment of Alzheimer’s disease. J Mol Graph Model. 2013;39:98−107.
   PubMed Web of Science ®Google Scholar
• Gu RX, Gu H, Xie ZY, et al. Possible drug candidates for Alzheimer’s disease deduced from studying their binding interactions with α7 nicotinic acetylcholine receptor. Med Chem. 2009;5(3):250−262.
   PubMed Web of Science ®Google Scholar
• Arias HR, Gu RX, Feuerbach D, et al. Different interaction between the agonist JN403 and the competitive antagonist methyllycaconitine with the human α7 nicotinic acetylcholine receptor. Biochemistry. 2010;49(19):4169−4180.
   PubMed Web of Science ®Google Scholar
• Zheng H, Wei DQ, Zhang R, et al. Screening for new agonists against Alzheimer’s disease. Med Chem. 2007;3(5):488−493.
   PubMed Web of Science ®Google Scholar
• Arias HR, Gu RX, Feuerbach D, et al. Novel positive allosteric modulators of the human α7 nicotinic acetylcholine receptor. Biochemistry. 2011;50(23):5263−5278.
   PubMed Web of Science ®Google Scholar
• Gotti C, Riganti L, Vailati S, et al. Brain neuronal nicotinic receptors as new targets for drug discovery. Curr Pharm Des. 2006;12(4):407−428.
   PubMed Web of Science ®Google Scholar